Assessment of Off-Label Usage of Antipsychotics in Middle Tennessee Nursing Homes

被引：0
|
作者：
Sheppard, Megan [1 ]
机构：
[1] Vanderbilt Univ, Sch Nursing, Nashville, TN 37240 USA
来源：
AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY | 2014年 / 22卷 / 03期
关键词：
D O I：
10.1016/j.jagp.2013.12.077
中图分类号：
R592 [老年病学]; C [社会科学总论];
学科分类号：
03 ; 0303 ; 100203 ;
摘要：
引用
收藏
页码：S71 / S71
页数：1
相关论文
共 50 条
  • [31] Off-label use of antidepressants, antipsychotics, and mood-stabilizers in psychiatry
    Gudrun Hefner
    Jan Wolff
    Sermin Toto
    Pamela Reißner
    Ansgar Klimke
    Journal of Neural Transmission, 2022, 129 : 1353 - 1365
  • [32] Reasons of Physicians Not to Discontinue Off-Label Use of Antipsychotics in People With ID
    De Kuijper, Gerda
    JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES, 2017, 10 : 195 - 195
  • [33] Off-Label Second Generation Antipsychotics for Impulse Regulation Disorders: A Review
    Beduin, Albertine Scheltema
    de Haan, Lieuwe
    PSYCHOPHARMACOLOGY BULLETIN, 2010, 43 (03) : 45 - 81
  • [34] Reduction of Off-Label Use of Antipsychotics in a Long Term Care Facility
    Burton, C. A.
    Thomas, C.
    Young, R.
    Na, C.
    Shepard, V.
    Shen, H.
    Ogar, J.
    Armstrong, J.
    Hadley, L.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2018, 66 : S273 - S273
  • [35] Reduction of Off-Label Use of Antipsychotics in a Long Term Care Facility
    Bieltz, Maureen
    Lantz, S.
    Whyte-Nagel, S.
    Zeigler, K.
    Tiesi, K.
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2018, 19 (03) : B21 - B22
  • [36] Off-label use of antipsychotics: when is the benefit/risk ratio favourable?
    Anand, R.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2009, 19 : S212 - S212
  • [37] OFF-LABEL TRASTUZUMAB USAGE IN BREAST CANCER PATIENT IN TURKEY
    Kockaya, G.
    Tanyeri, P.
    Buyukokuroglu, M. E.
    Yenilmez, F. B.
    Durmus, D.
    Vural, I. M.
    Akbulat, A.
    Artiran, G.
    Gursoz, H.
    Kerman, S.
    VALUE IN HEALTH, 2013, 16 (07) : A396 - A397
  • [38] A multicenter assessment of recombinant factor VIIa off-label usage: clinical experiences and associated outcomes
    MacLaren, R
    Weber, LA
    Brake, H
    Gardner, MA
    Tanzi, M
    TRANSFUSION, 2005, 45 (09) : 1434 - 1442
  • [39] Reduced risk of mortality and antipsychotics in Parkinson's diseaserelated psychosis: pimavanserin vs off-label antipsychotics
    Isaacson, S.
    Pagan, F.
    Truong, D.
    Abler, V.
    Pahwa, R.
    MOVEMENT DISORDERS, 2022, 37 : S368 - S368
  • [40] Off-label use of second generation antipsychotics in all Austrian inpatient population
    Konstantinidis, A.
    Moser, U.
    Darau, C.
    Grohmann, R.
    Engel, R.
    Kasper, S.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 141 - 141
12345